Efficacy of artificial femoral head replacement for femoral head avascular necrosis

Shou-Feng Wang, MMa, Qing-Hui Ji, MMb, Xiao-Feng Qiao, MMa, Peng Zhao, MMb, Yu Xue, MBc, Yan-Bao Li, MMa,∗

Abstract
Background: Femoral head avascular necrosis (FHAN) is one of the most common progressive orthopedic disorders. Previous studies have reported that artificial femoral head replacement (AFHR) can effectively treat patients with FHAN. However, no systematic review has investigated the efficacy of AFHR for FHAN. This study will assess the efficacy of AFHR for patients with FHAN.

Methods: We will search MEDLINE, EMBASE, Web of Science, Cochrane Library, Chinese Biomedical Literature Database, and China National Knowledge Infrastructure up to March 1, 2019 without any restrictions. Any randomized controlled trials for assessing the efficacy of AFHR for patients with FHAN. The methodological quality for each eligible study will be assessed by using Cochrane risk of bias tool. Statistical analysis will be conducted by using RevMan 5.3.

Results: This study will provide current evidence of AFHR for patients with FHAN from several aspects, including pain intensity, function, and limitation of femoral head, health-related quality of life, and safety.

Conclusion: This study will provide latest evidence on assessing the efficacy and safety of AFHR for FHAN.

PROSPERO registration number: PROSPERO CRD42019126249.

Abbreviations: AFHR = artificial femoral head replacement, CIs = confidence intervals, FHAN = femoral head avascular necrosis, RCTs = randomized controlled trials.

Keywords: artificial femoral head replacement, avascular necrosis, efficacy, femoral head, randomized controlled trial

1. Introduction
Femoral head avascular necrosis (FHAN) is a common disorder of the hip joint.1-3 If it cannot be treated fairly well, it can frequently cause the damage of femoral head and degradation of hip joints.4-6 Unfortunately, current treatments still had limited efficacy.7-9 Furthermore, it can be further aggravated by using steroid, alcoholic intake, sickle cell anemia, metabolic disorders, tumors, or trauma.10-12 Previous study reported that the incidence of FHAN was about 10,000 to 20,000 new cases in the United States.11,12 Impaired blood perfusion and increased intraosseous pressure mainly account for the necrotic process.12,13 If these conditions cannot be identified at early stages, they may result in osteoarthritis and finally need joint replacement.

Previous clinical trials have reported that joint replacement, especially artificial femoral head replacement (AFHR) can treat this disorder very effectively.13,14-26 Unfortunately, no study has systematically assessed the efficacy of AFHR for the treatment of FHAN. Therefore, this study will first evaluate the efficacy of AFHR for patients with FHAN.

2. Methods
2.1. PROSPERO registration
This study has been registered on PROSPERO (CRD42019126249). Its report follows Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) Protocols statement guidelines.12,27

2.2. Eligibility criteria for study selection
2.2.1. Types of studies. Randomized controlled trials (RCTs) assessing the efficacy and safety of AFHR for FHAN will be considered for inclusion without any restrictions. Noncontrolled trials, non-RCTs, and quasi-RCTs will be excluded.

2.2.2. Types of participants. All patients who have been diagnosed with FHAN will be included without any limitations of region, race, gender, and so on.

2.2.3. Type of interventions. All patients in the experimental group receive any kinds of AFHR. It will be excluded if the
patients receive AFHR with other treatments. All patients in the
treatment group can receive any therapies, but not the AFHR.

2.2.4. Type of outcomes. Primary outcome is pain intensity, as
measured by any pain scales, such as visual analog scale.
Secondary outcomes include function and limitation of attacked
femoral head, as measured by Western Ontario and McMaster
University Osteoarthritis Index, or any other tools; health-
related quality of life, as assessed by 36-Item Short Form Health
Survey; and any complications after the surgery.

2.3. Search strategy

The following electronic databases of Cochrane Library, MED-
LINE, EMBASE, Web of Science, Chinese Biomedical Literature
Database, and China National Knowledge Infrastructure will be
searched up to March 1, 2019 without any restrictions. In addition,
we will also search dissertations, clinical registry, and reference lists
of relevant reviews. We will provide search strategy sample for
MEDLINE in Table 1. Additionally, identical search strategies will
also be built and utilized to other electronic databases.

2.4. Data collection

2.4.1. Study selection. This study selection has 2 phrases. At the
first phrase, 10 authors will screen the titles and abstracts of all
records independently to exclude studies obviously failing to the
eligibility criteria. At second phrase, the full-texts of remaining
studies will be read by the same 2 authors to further determine
whether they finally meet all eligibility criteria for inclusion. Any
disagreements will be solved by a third author through
discussion. The results of the study selection process will be
presented in the PRISMA flowchart.

2.4.2. Data extraction. Two authors will collect all important
information and extract data based on the predesigned data
extraction sheet independently. All disagreements will be
resolved by judging from a third author through discussion. The
extracted information comprises of study details, such as
author, country, year of publication, and so on; patient details,
such as characteristic data at baseline, diagnostic criteria, and so
on; study methods, such as sample size, randomization, blinding,
and so on; treatments details in both experimental and control
group; and all outcome measurements.

2.4.3. Missing data. If any data are unclear or not reported in
the primary study, we will contact the primary authors by email
or phone to inquire them if it is possible. Otherwise, we will
analyze the available information and will also carry out
sensitivity analysis to investigate the potential effect of the
missing data.

2.5. Methodological quality assessment

Two authors will evaluate the methodological quality for each
eligible study according to the standard criteria of Cochrane
Collaboration Tool independently. It comprises of 7 aspects, and
each aspect will be classified into 3 levels: high, unclear, or low
risk of bias. Any disagreements will be solved by a third author
through discussion.

2.6. Statistical analysis

We will use RevMan 5.3 software to conduct statistical analysis,
including data pooled, and meta-analysis performance.

2.6.1. Treatment effect measurement. Continuous data will
be recorded as mean difference or standardized mean difference
and 95% confidence intervals (CIs). Dichotomous data will be
recorded as risk ratio and 95% CIs.

2.6.2. Heterogeneity assessment. Heterogeneity among all
eligible studies will be determined by utilizing $I^2$ test. When $I^2
\leq 50\%$, heterogeneity is considered as minor. When $I^2 >50\%$,
heterogeneity is considered as significant.

2.6.3. Data synthesis. When heterogeneity is minor, we will use
a fixed-effect model to synthesize data and will perform meta-
analysis if it is possible. When heterogeneity is significant, we will
analyze the causes of the heterogeneity by carrying out subgroup
analysis or meta-regression analysis. When heterogeneity is minor
after subgroup analysis, we will still pool the data and conduct the
meta-analysis. When heterogeneity is still significant, the data will
not be pooled, and narrative descriptions will be reported.

2.6.4. Subgroup analysis. When heterogeneity is significant,
subgroup analysis will be operated based on the different study
characteristics, interventions, and outcomes.

2.6.5. Sensitivity analysis. Sensitivity analysis will be carried
out to examine the robustness of data pooled results by taking
away low-quality RCTs.

3. Discussion

FHAN is a very common disorder among elderly population. It
greatly affects quality of life for patients with this condition.
Previous studies have reported that several managements can
help to relieve this disorder. However, the efficacy is not satisfied.
Fortunately, joint replacement, especially as for AFHR has been
reported to treat this condition fairly well and can significantly


| Table 1 |
| --- |
| **Search strategy applied in MEDLINE database.** |
| **Number** | **Search terms** |
| 1 | Avascular necrosis |
| 2 | Femoral head |
| 3 | ANV |
| 4 | Femoral head |
| 5 | Head |
| 6 | Necrosis |
| 7 | Or/1–6 |
| 8 | Randomized controlled trial |
| 9 | Controlled clinical trial |
| 10 | Randomly |
| 11 | Randomized |
| 12 | Trial |
| 13 | Or/8–12 |
| 14 | Artificial femoral head replacement |
| 15 | Femoral head |
| 16 | Joint replacement |
| 17 | Artificial |
| 18 | Or/14–17 |
| 19 | 7 and 13 and 18 |
improve the quality of life for patients with FHAN. To our best knowledge, this study will firstly and systematically investigate the efficacy of AFHR for patients with FHAN. The results of this study will provide very helpful evidence to determine whether AFHR is an effective management for patients with FHAN. The findings will also summarize helpful evidence for both patients and doctors.

Author contributions
Conceptualization: Shou-Feng Wang, Xiao-Feng Qiao, Peng Zhao, Yu Xue, Yan-Bao Li.
Data curation: Shou-Feng Wang, Qing-Hui Ji, Xiao-Feng Qiao, Yan-Bao Li.
Formal analysis: Shou-Feng Wang, Qing-Hui Ji.
Funding acquisition: Shou-Feng Wang.
Investigation: Yan-Bao Li.
Methodology: Shou-Feng Wang, Qing-Hui Ji, Xiao-Feng Qiao.
Project administration: Yan-Bao Li.
Resources: Shou-Feng Wang, Qing-Hui Ji, Xiao-Feng Qiao, Peng Zhao, Yu Xue.
Software: Shou-Feng Wang, Qing-Hui Ji, Xiao-Feng Qiao, Peng Zhao, Yu Xue.
Supervision: Yan-Bao Li.
Validation: Qing-Hui Ji, Yu Xue, Yan-Bao Li.
Visualization: Xiao-Feng Qiao, Yan-Bao Li.
Writing – original draft: Shou-Feng Wang, Qing-Hui Ji, Xiao-Feng Qiao, Peng Zhao, Yu Xue, Yan-Bao Li.
Writing – review and editing: Shou-Feng Wang, Qing-Hui Ji, Peng Zhao, Yu Xue, Yan-Bao Li.

References
[1] Manenti G, Althobelli S, Pugliese L, et al. The role of imaging in diagnosis and management of femoral head avascular necrosis. Clin Cases Miner Bone Metab 2015;12(Suppl 1):31–8.
[2] Ehlinger M, Moser T, Adam P, et al. Early prediction of femoral head avascular necrosis following neck fracture. Orthop Traumatol Surg Res 2011;97:79–88.
[3] Orban H, Cirstoiu C, Adam R. Total hip arthroplasty in secondary systemic lupus erythematosus femoral head avascular necrosis. Rom J Intern Med 2007;45:123–9.
[4] Kerachian MA, Seguin C, Harvey EJ. Glucocorticoids in osteonecrosis of the femoral head: a new understanding of the mechanisms of action. J Steroid Biochem Mol Biol 2009;114:121–8.
[5] Ancelin D, Reina N, Cavaignac E, et al. Total hip arthroplasty survival in femoral head avascular necrosis versus primary hip osteoarthritis: case-control study with a mean 10-year follow-up after anatomical cementless metal-on-metal 28-mm replacement. Orthop Traumatol Surg Res 2016;102:1029–34.
[6] Raipur S, Kulkarni B. Bilateral femoral head avascular necrosis with physiological doses of steroids. Indian J Endocrinol Metab 2018;22:710–1.
[7] Signorino JA, Jayaseelan DJ, Bridle K. Atypical clinical presentation of rapidly progressing femoral head avascular necrosis. J Orthop Sports Phys Ther 2017;47:217.
[8] Gao YH, Li SQ, Wang YF, et al. Arthroplasty in patients with extensive femoral head avascular necrosis: cementless arthroplasty in extensive femoral head necrosis. Int Orthop 2015;39:1307–11.
[9] Bjorkman A, Svensson PJ, Hillarp A, et al. Factor V leiden and prothrombin gene mutation: risk factors for osteonecrosis of the femoral head in adults. Clin Orthop Relat Res 2004;425:168–72.
[10] Browner WS, Luy LY, Cummings SR. Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women. J Clin Endocrinol Metab 2001;86:631–7.
[11] Lieberman JR, Berry DJ, Mont MA, et al. Osteonecrosis of the hip: management in the 21st century. Instr Course Lect 2003;52:337–55.
[12] Elmalı N, Ertem K, Karakaplan M, et al. Vascular pedicled iliac bone grafting is effective in patients with an early stage of femoral head avascular necrosis. Eklem Hastalik Cerrahisi 2014;25:2–7.
[13] Gomez JA, Matsumoto H, Roys DP Jr, et al. Articulated hip distraction: a treatment option for femoral head avascular necrosis in adolescence. J Pediatr Orthop 2009;29:163–9.
[14] Xia H, Du ZJ. Total hip arthroplasty and bipolar artificial femoral head replacement for avascular necrosis of the femoral head. Hand Surg 2017;23:131–3.
[15] Wu Qing, Comparison of total hip arthroplasty and bipolar artificial femoral head replacement for the treatment of avascular necrosis of the femoral head in the elderly. China Pract Med 2016;11:72–3.
[16] Yu Wanchu. Comparison of total hip arthroplasty and bipolar artificial femoral head replacement for the treatment of avascular necrosis of the femoral head in the elderly. Chin Contemp Med 2014;21:47–8.
[17] Geng CY, Duan LF. Artificial femoral head replacement for the treatment of avascular necrosis of the femoral head. Clin Med 2013;33:71–2.
[18] Jin P, He FP, Wang J. Comparison of total hip arthroplasty and bipolar artificial femoral head replacement for the treatment of avascular necrosis of the femoral head in the elderly. Chin Med Innov 2013;10:15–7.
[19] Hou MG. Effect of modified small femoral lateral incision artificial femoral head replacement for avascular necrosis of the femoral head. Chin Foreign Med Care 2013;32:52–3.
[20] Cai WP, Li SD, Kang TF, et al. Treatment of femoral neck fracture and femoral head avascular necrosis with small incision artificial femoral head and hip replacement. Gansu Med J 2012;31:691–2.
[21] Hu W, Bai B, Liao ZW, et al. Comparison of bipolar artificial femoral head and total hip arthroplasty in the mid-and long-term follow-up of Ficat III stage of avascular necrosis of the femoral head in elderly patients. Chin J Joint Surg 2012;6:196–200.
[22] Jing X. Bipolar artificial femoral head replacement for the treatment of femoral head necrosis. Foreign Med Sci (Orthoped) 2001;37:61–2.
[23] Han W, Tian W, Tian XB, et al. Comparison of artificial femoral head replacement and total hip replacement for femoral neck fracture and avascular necrosis of the femoral head. Guizhou Med J 2000;23:304.
[24] Li JL, Fan YN, Qiao JM, et al. One-time replacement of artificial femoral head with bilateral femoral head necrosis. J Jiamusi Med Coll 1995;18:46–7.
[25] Ding SF, Liu SC, Qian JF, et al. Analysis of 43 cases of advanced avascular necrosis of the femoral head treated with artificial femoral head and total hip arthroplasty. J Jining Med Coll 1993;15:34.
[26] Fan YN, Zhang YH, Qiao JM, et al. The experience of artificial femoral head replacement for avascular necrosis of the femoral head. Henan J Surg 2017;23:131–3.
[27] Sutton AJ, Duval SJ, Tweedie RL, et al. Empirical assessment of effect of publication bias on meta-analyses. BMJ 2000;320:1574.
[28] Shamseer L, Moher D, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ 2015;349:g7647.
[29] Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629–34.